Low-dose fotemustine as second-line chemotherapy for recurrent glioblastoma multiforme

Francesca De Felice, Nadia Bulzonetti, Daniela Musio, Alessandro D'Elia, Maurizio Salvati, Vincenzo Tombolini

Research output: Contribution to journalArticlepeer-review


Aim: To test if fotemustine administrated at low doses during the maintenance phase of gioblastoma therapy could improve the toxicity profile, without reducing progression-free survival at six months (PFS-6). Patients and Methods: Patients enrolled were affected by recurrent glioblastoma multiforme, proven by magnetic resonance imaging (MRI), at least six months after radiochemotherapy completion. Fotemustine was administered at an induction dose of 100 mg/m2 followed by a maintenance dose of 75 mg/m2. Results: All 15 patients completed the induction phase. Eight patients began maintenance-phase therapy and received a median of three cycles (range=2-6). Grade 3 or more haematological toxicity was not documented. The PFS-6 was 5/15 and the median overall survival was 7.5 months. Conclusion: Haematological toxicity compares favourably with trials using the conventional scheme: no grade 3-4 adverse effects were recorded. This low-dose approach could be considered a compromise treatment whilst waiting for definitive standardization of second-line therapy, in order to reduce severe hematological toxicity.

Original languageEnglish
Pages (from-to)4013-4016
Number of pages4
JournalAnticancer Research
Issue number9
Publication statusPublished - Sep 2013


  • Chemotherapy
  • Fotemustine
  • Glioblastoma
  • Low-dose
  • Second-line therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Low-dose fotemustine as second-line chemotherapy for recurrent glioblastoma multiforme'. Together they form a unique fingerprint.

Cite this